• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cabaletta Bio Inc.

    4/23/24 7:05:49 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CABA alert in real time by email
    DEFA14A 1 d448465ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    CABALETTA BIO, INC.

    (Name of registrant as specified in its charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


      LOGO

     

      P.O. BOX 8016, CARY, NC 27512-9903

     

    LOGO

       LOGO

     

     

     

    Cabaletta Bio, Inc.

     

    Annual Meeting of Stockholders

     

    Monday, June 3, 2024 at 9:00 AM, Eastern Time

    Annual Meeting to be held live via the internet - please visit www.proxydocs.com/CABA for more details

     

    You must pre-register to attend the meeting online at www.proxydocs.com/CABA

     

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/CABA

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.

     

    If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 24, 2024.

      

    LOGO

     

      

    Scan QR for  

    digital voting  

     

     

     

     

     

    Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 3, 2024 For Stockholders of record as of April 4, 2024

     

    To order paper materials, use one of the following methods.

     

      LOGO

     

    Internet:

    www.investorelections.com/CABA

     

      LOGO

    Call:

    1-866-648-8133

     

      LOGO

    Email:

    [email protected]

     

    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

     

    LOGO

         

    Have the 12 digit control number located in the

    box above available when you access the

    website and follow the instructions.

    SEE REVERSE FOR FULL AGENDA      

    Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO   Cabaletta Bio, Inc. Annual Meeting of Stockholders

    The Board of Directors Recommends a Vote FOR the director nominees listed in Proposal 1 and FOR Proposal 2.

     

     

     

    PROPOSAL

     

    1.    To elect two class II directors to our board of directors, to serve until the 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal.   
       1.01 Catherine Bollard, MBChB, M.D.      
       1.02 Richard Henriques, MBA   
    2.    To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.   
       NOTE: To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
    Get the next $CABA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CABA

    DatePrice TargetRatingAnalyst
    10/10/2025$14.00Buy
    Jefferies
    12/20/2024$15.00 → $6.00Outperform → In-line
    Evercore ISI
    12/19/2024$12.00 → $6.00Overweight → Equal Weight
    Wells Fargo
    10/10/2024$10.00Buy
    UBS
    2/5/2024$36.00Buy
    Jefferies
    11/29/2023$38.00Outperform
    William Blair
    10/24/2023$40.00Overweight
    Cantor Fitzgerald
    10/19/2023$31.00Buy
    Stifel
    More analyst ratings

    $CABA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tomasello Shawn bought $50,322 worth of shares (22,725 units at $2.21) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:55:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 9:30 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company's website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (NASDAQ:CABA) is a

    2/5/26 8:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Announces 2026 Strategic Priorities

    Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose  IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics New durability data without preconditioning and higher dose initial clinical data from RESET-PV™ expected in 1H26; dose-ranging data from RESET-SLE™ without preconditioning anticipated in 2026 Complete Phase 1/2 data anticipated in lupus, scleroderma and myasthenia

    1/12/26 8:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms

    The first GMP cell therapy product ever manufactured for clinical use on the Cell Shuttle™ and released using Cell Q™, is expected to be infused into patients within Cabaletta's RESET™ clinical trial program in the first half of 2026. Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio's (NASDAQ:CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has received FDA clearance of an IND Amendment (INDa) to use Cellares' Cell Shuttle™ and Cell Q™ platforms for manufacturing and QC release testing. The clearance allows for the clinical manufacturing and release of rese-cel using Cellares' fully automated

    1/12/26 7:30:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tomasello Shawn bought $50,322 worth of shares (22,725 units at $2.21) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:55:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Cabaletta Bio with a new price target

    Jefferies resumed coverage of Cabaletta Bio with a rating of Buy and set a new price target of $14.00

    10/10/25 8:36:11 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously

    12/20/24 7:29:05 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously

    12/19/24 7:31:17 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    SEC Filings

    View All

    Cabaletta Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cabaletta Bio, Inc. (0001759138) (Filer)

    1/12/26 8:02:10 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Cabaletta Bio Inc.

    SCHEDULE 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    11/14/25 8:06:51 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Cabaletta Bio Inc.

    SCHEDULE 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    11/14/25 4:09:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Leadership Updates

    Live Leadership Updates

    View All

    Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

    Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort met the registrational, 16-week primary endpoint Planned BLA submission for rese-cel in 2027 based on 14-patient, single-arm DM/ASyS registrational cohort initiating enrollment this quarter within the RESET-Myositis™ trial FDA alignment on additional registrational cohort designs for RESET-SSc™ and RESET-SLE™ anticipated by year-end 2025 PHILADEL

    11/10/25 7:30:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

    – Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the appointment of Steve Gavel as Chief Commercial Officer, effective immediately. In his role, Mr. Gavel will join the leadership team and will lead all aspects of global commercial strategy and execution for rese-cel (resecabtagene autoleucel, formerly CABA-201), for

    10/14/25 8:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

    – Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 20

    7/24/23 8:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Financials

    Live finance-specific insights

    View All

    Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

    – CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period – – Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional naïve B cell repopula

    11/18/24 7:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

    – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International – – Cash, cash

    11/14/24 7:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

    – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients' specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all disease-specific therapies other than a planned steroid taper in one patient – – Immature, naïve B cell repopulation in first IMNM patient observed at week 8 consistent with a potential immu

    6/14/24 2:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 4:50:19 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 3:36:55 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care